|
End-of-day quote
Korea S.E.
23/09/2026
|
5-day change | 1st Jan Change | ||
| 8,180.00 KRW | +12.21% |
|
+16.86% | +19.94% |
| 09/12 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/06/25 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | 3.44x | - | 33.52x | 141M | |
| -.--% | -.--% | -300.09x | 30.36x | 19.89x | -357.13x | -260.84x | 58.92B | |
| 0.94% | 0.95% | 22.17x | 2.79x | 2.05x | 11.58x | 13.84x | 25.06B | |
| 5.66% | 5.78% | 15.67x | 1.1x | 1.21x | 6.87x | 12.73x | 6.55B | |
| 0.95% | 1.03% | 52.92x | 11.48x | 9.79x | 33.68x | 41.8x | 3.41B | |
| -.--% | -.--% | -66.03x | - | - | - | - | 2.51B | |
| 5.22% | 6.06% | 15.6x | 2.25x | 1.66x | 6.48x | 10.58x | 2.3B | |
| 1.36% | 2.03% | 33.22x | 1.92x | 1.75x | 13.1x | 22.33x | 2B | |
| 0.81% | 1.34% | 32.8x | 1.93x | 1.21x | 9.59x | 13.95x | 1.89B | |
| 0.11% | 0.12% | 69.92x | 13.51x | 15.47x | 36.72x | 48.65x | 1.64B | |
| 3.51% | 3.53% | 40.58x | 1.45x | 0.86x | 7.27x | 24.75x | 1.23B | |
| 0.25% | 0.29% | 39.61x | 2.98x | - | - | - | 1.23B | |
| 1.94% | 2.25% | 43.16x | 14.18x | - | - | - | 939M | |
| 3.39% | 3.8% | 18.34x | 1.06x | - | - | - | 869M | |
| Average | 1.86% | 2.09% | 1.38x | 7.08x | 5.73x | -25.76x | -3.87x | 7.76B | |
| Weighted average by Cap. | 0.83% | 0.89% | -152.69x | 18.48x | 12.61x | -198.67x | -141.41x |
- Stock Market
- Stocks
- A340450 Stock
- Sector GC Genome Corporation
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
